Junshi Receives China’s NMPA Acceptance for Toripalimab Injection

Why It Matters

The subcutaneous version simplifies administration, potentially expanding access and adherence for Chinese cancer patients, and positions Junshi as a pioneer in domestic immunotherapy delivery.

Key Takeaways

• NMPA accepted subcutaneous toripalimab NDAs for 12 indications
• First domestic anti‑PD‑1 antibody in subcutaneous form
• Phase III study shows non‑inferior exposure vs IV
• Subcutaneous delivery expected to boost patient adherence
• Collaboration with LEO Pharma expands toripalimab to Europe

Pulse Analysis

Toripalimab, a PD‑1 checkpoint inhibitor, has become a cornerstone of immuno‑oncology in China, competing with imported antibodies such as pembrolizumab. By reformulating the drug for subcutaneous injection, Junshi addresses a long‑standing logistical hurdle: the need for lengthy intravenous infusions in hospital settings. Subcutaneous delivery reduces chair time, lowers infusion‑related costs, and aligns with a global trend toward patient‑centric oncology care, where convenience directly influences treatment continuity.

The National Medical Products Administration’s acceptance of JS001sc’s new‑drug applications signals regulatory confidence in the product’s safety and efficacy. Data from the multicenter Phase III JS001sc‑002‑III‑NSCLC trial showed that the subcutaneous formulation achieved exposure levels that were statistically non‑inferior to the intravenous version, with similar response rates and manageable safety profiles. Covering all approved indications of toripalimab, the NDAs open a pathway for rapid market entry across multiple tumour types, potentially reshaping the domestic immunotherapy landscape and prompting competitors to explore alternative delivery routes.

Beyond China, Junshi’s partnership with LEO Pharma positions the company to leverage European distribution networks, extending toripalimab’s reach into mature markets. This dual‑market strategy could accelerate revenue diversification and reinforce Junshi’s reputation as an innovative biotech. As oncology shifts toward combination regimens and long‑term maintenance therapy, a convenient subcutaneous option may become a differentiator, driving higher patient adherence and creating new pricing and reimbursement opportunities across regions.